• Accueil >
  • Publications >
  • Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01

23 janv. 2019Science Translational Medicine

DOI : 10.1126/scitranslmed.aat9321

Auteurs

Guillem Pascual-Pasto, Miriam Bazan-Peregrino, Nagore G. Olaciregui, Camilo A. Restrepo-Perdomo, Ana Mato-Berciano, Daniela Ottaviani, Klaus Weber, Genoveva Correa, Sonia Paco, Monica Vila-Ubach, Maria Cuadrado-Vilanova, Helena Castillo-Ecija, Gaia Botteri, Laura Garcia-Gerique, Helena Moreno-Gilabert, Marta Gimenez-Alejandre, Patricia Alonso-Lopez, Marti Farrera-Sal, Silvia Torres-Manjon, Dolores Ramos-Lozano, Rafael Moreno, Isabelle Aerts, François Doz, Nathalie Cassoux, Elodie Chapeaublanc, Montserrat Torrebadell, Monica Roldan, Andrés König, Mariona Suñol, Joana Claverol, Cinzia Lavarino, Torres Carmen de, Ligia Fu, François Radvanyi, Francis L. Munier, Jaume Catalá-Mora, Jaume Mora, Ramón Alemany, Manel Cascalló, Guillermo L. Chantada, Angel M. Carcaboso

Résumé

An oncolytic adenovirus shows antitumor efficacy in patient-derived models of intraocular retinoblastoma and appears safe for human use.

Membres

FRANCOIS RADVANYI

Directeur de recherche